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T
he development of RNA inter-
ference (RNAi) as a tool for 
knocking down genes has revol-
utionized the study of gene/protein 
function for biologists. With relative ease, 
researchers can knock down their gene 
of interest by introducing double-stranded 
RNA into their cell 
system. Indeed that’s 
precisely how Liu 
first came across 
RNAi. But Liu then 
became hooked on 
the question of how it 
works.
When dsRNA is 
introduced into cells, 
it is fi  rst  chopped 
into shorter, 21–26-
nucleotide pieces 
called siRNA, which 
then get incorporated into an RNA-
induced silencing complex (RISC). With 
the siRNAs on board, the RISC complex 
can target, cleave, and degrade particular 
mRNAs. Liu and collaborators discovered 
the RISC component responsible for the 
cleavage step (1, 2).
Liu has also made headway in deter-
mining the mechanism of endogenous 
RNAi, in particular the role of processing 
bodies (P-bodies)—cytoplasmic depots 
for many RNAi factors (3, 4).
Liu recently moved to the Sloan Ket-
tering Institute in New York to set up his 
own laboratory. He is in the fi  rst fl  urry of 
grant writing and staff hiring, but he 
nonetheless found time to chat about his 
P-body passion.
AN EARLY START IN CHINA
When did your ﬁ  rst interest in science 
develop?
My father is a chemist, and when I was a 
kid he would bring me to his lab. I spent 
a lot of time there. Then, when I was in 
high school, I became increasingly 
interested in chemistry and biochemistry. 
I decided to go to college with biochem-
istry as a major.
Where was college for you?
I went to Nankai University in Tianjin, 
which is my hometown and one of the larg-
est cities in the northeastern part of China.
And then you moved to the states?
Yes, back in ’95. I did my Ph.D. studies in 
biochemistry and biophysics with Dr. Yue 
Xiong at UNC Chapel Hill.
What made you leave China?
At that time in China, most of the univer-
sities didn’t have enough resources to 
carry out cutting-edge biomedical research. 
Like lots of my classmates, I applied to 
graduate programs in the U.S. to get 
further education.
SWITCH TO SILENCING
Your Ph.D. studies were on ubiquitin-
mediated degradation. So how did you 
become interested in RNAi?
For one of my last experiments as a grad-
uate student, I used RNAi to knock down 
my favorite gene and study its function. 
It helped me graduate!
At that time I realized how powerful 
the technique was. But people didn’t 
know the mechanism involved. That got 
me thinking.
You graduated in 2002 and moved to 
Cold Spring Harbor. What was the main 
premise of your postdoctoral project?
Back then, people knew that siRNAs 
could lead to the degradation of the tar-
get mRNAs, but they didn’t know how. I 
joined Greg Hannon’s lab at CSH as a 
postdoctoral fellow to study the mecha-
nisms of RNAi and took advantage of 
my previous training in studying protein 
function.
The fi  rst approach was to look for 
proteins that directly interact with the 
siRNA. We found that one of the RISC 
components, Argonaute, binds directly to 
the siRNA. Then, later on, we found out 
that Argonaute itself functions as the slicer 
enzyme that cleaves the target mRNA.
Once cleaved, the mRNA is defective 
and will be degraded. That’s how siRNA 
leads to the degradation of its targets.
That led to a publication in Science very 
early in your career. Would you say that 
was the highlight of your career so far?
The Science paper was obviously a quite 
exciting and important fi  nding, but on the 
other hand, we were really expecting to 
fi  nd a new enzyme that cleaved the tar-
gets. Argonaute had been known for 
several years; we just didn’t know its 
exact function. Obviously, you always 
hope to fi  nd a novel protein so you’ll have 
more to work on. But instead it was kind 
of the end of that chapter. So in a way, it 
was a little disappointing. You shouldn’t 
write that…[laughs].
What else did you work on as a postdoc?
We wanted to find the endogenous/
physiological function of the RNAi ma-
chinery. The fi  rst endogenous small RNA 
(currently known as miRNA) was discov-
ered back in 1993 in C. elegans. However, 
the real signifi  cance of the discovery was 
not realized until 2000/2001 when several 
groups reported the presence of large 
numbers of miRNAs in both invertebrates 
and vertebrates. Such conservation sug-
gested they were important.
Sequence specifi  city of RNA silencing 
is based on base pairing between the small 
RNA and the potential targets. In the case 
of siRNAs, the targets are perfectly 
matched. But for the miRNA, you don’t 
necessarily have perfectly matched targets.
If the targets are not perfectly matched, 
they cannot go through the cleavage and 
degradation steps. However, those targets 
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can still be silenced by the miRNA. So the 
question was, How does miRNA silence 
gene expression?
And?
It’s still the biggest unanswered question. 
It’s related to siRNA-mediated silencing. 
They both use the same core protein com-
ponents: the Argonaute proteins and the 
RNA-induced silencing complex (RISC), 
but the mechanisms are different.
What are the theories?
Some studies have shown that miRNA can 
lead to mRNA degradation just like siRNA 
does, although it doesn’t cleave its targets. 
It’s possible that miRNA and Argonaute 
could lead to deadenylation of the target 
mRNAs, which would then lead to degra-
dation of the mRNA. Other studies have 
shown that there’s no degradation at all but 
that miRNA instead represses mRNA trans-
lation. Almost all the steps of translation 
including initiation, elongation, and ter-
mination have been suggested as the 
mechanism of miRNA-mediated silencing.
We showed miRNA could lead to the 
sequestration of target mRNAs into cyto-
plasmic bodies, and this prevented the 
mRNAs from being translated. Other 
studies suggested sequestration is not 
required, but that binding of Agonaute/
RISC to the mRNAs is suffi  cient to si-
lence them. Everyone seems to agree that 
miRNA will silence gene expression, but 
the exact mechanism is still highly debated.
SITES OF SILENCING
These cytoplasmic bodies you 
mentioned are P-bodies?
Yes. We decided to look at where the pro-
tein components that carry out the silenc-
ing localize in the cell. We found, back in 
2003, that argonaute proteins localized into 
very specifi  c foci in the cytoplasm. At that 
stage we didn’t know what the foci were. It 
was just a very interesting observation.
People fi  rst observed similar foci back 
in ’97. They found that a nuclease that 
degrades mRNA localizes into specifi  c 
foci in the cell. But again, at that time, 
nothing was known in terms of function. 
Later, Roy Parker’s group showed that 
mRNA decapping and degradation occurs 
in these P-bodies.
The formation of P-bodies is RNA 
dependent. So, it’s a complicated situation: 
you need mRNA to form those foci, but if 
the foci’s purpose is to just degrade 
mRNA, then if they do a good job, you 
shouldn’t see them, right?
So when you see them, either they are 
not effi  ciently degrading those mRNAs so 
you see the accumulation, or these foci 
may function to sequester and store the 
mRNA, not degrade it. The P-bodies 
could just sequester mRNAs away from 
the translational machinery.
Could they do both?
I think whether mRNA will be degraded 
might depend on the protein complex 
associated with that particular mRNA. 
Obviously, we haven’t fi  gured out what 
proteins decide these fates yet.
But that could explain why there are so 
many different reports: some groups see 
mRNA degradation and some groups don’t. 
Perhaps the P-body functions like a sorting 
machine for either degrading or protecting 
and sequestering mRNA. Of course, 
miRNA is just one branch that can bring 
mRNA into P-bodies. There are several 
other pathways, like nonsense-mediated or 
ARE-mediated RNA decay. These could 
provide the mRNA substrates and trigger 
P-body formation. Clearly, in these cases, 
mRNA will be degraded eventually.
What are the next big P-body questions?
What are the components of P-bodies? 
Are all P-bodies the same or different? 
How do they assemble together and what 
regulates their assembly? Also, how does 
sequestered mRNA get back into cyto-
plasm for translation?
Wow, those are pretty big questions. 
How do you hope to answer them?
From the cell biology point of view, we 
have a long list of P-body components. We 
want to study whether these colocalize in 
the same P-bodies, 
what are their par-
ticular functions, 
and how do they 
modulate the si-
lencing activity of 
miRNA?
We are also 
trying to purify P-
bodies. Right now 
there is no bio-
chemical way to 
purify them, so it’s 
hard to argue as to 
what percentage 
of the RISC or silenced mRNA is in the 
P-body as opposed to in the cytoplasm.
Also, a major question for the miRNA 
fi  eld is, What are the real genes that they 
repress? Because miRNAs are not per-
fectly matched to their targets, genome 
database searches give you hundreds of 
potential hits. There are very few con-
fi  rmed miRNA targets at this point.
If we can biochemically purify P-bod-
ies, and if our idea about sequestering is 
right, then the important targets should be 
there in the P-bodies.
That’s a lot to keep you occupied!
Yeah, the P-body fi  nding—that it could 
function as both the degradation sites for 
mRNA and the storage sites for trans-
lationally repressed mRNA—I think is 
exciting. It kind of opens up a new fi  eld, 
a new direction for research.
1.  Liu, J., et al. 2004. Science. 305:1437–1441.
2.  Song, J.J., et al. 2004. Science. 
305:1434–1437.
3.  Liu, J., et al. 2005. Nat. Cell Biol. 7:719–723.
4.  Liu, J., et al. 2005. Nat. Cell Biol. 
7:1261–1266.
P-bodies are thought to be the sites of 
silencing, as they contain the RISC factor 
Argonaute (green).
“If we can 
biochemically 
purify P-bodies, 
and if our 
idea about 
sequestering is 
right, then the 
important targets 
should be there 
in the P-bodies.”